Observational studyAmerican journal of respiratory and critical care medicine2022
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
Registry-linked trialOpen access · greenAbstract readObservational Study
In one paragraph
Observational study in American journal of respiratory and critical care medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06837181 (Studying the Presence of CFRD Complications With Thoughtful Recruitment), which is not on this map. Cited by 198 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
198citing papers in PubMed, 1 pooled it
35.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
Who cites it
198 citing papers in PubMed, 1 synthesis or guideline pooled it, 363 citations in OpenAlex.
- Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Impact of 2 years of treatment with elexacaftor/tezacaftor/ivacaftor on longitudinal changes in structural lung disease in people with cystic fibrosis: results from the RECOVER trial.Annals of the American Thoracic Society · 2026Trial
- Evaluation of the drug interaction between rifabutin and elexacaftor/tezacaftor/ivacaftor (ETI).Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026Trial
- Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial.American journal of respiratory and critical care medicine · 2025Trial
- Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.The Lancet. Respiratory medicine · 2025Trial
- The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024Trial
- Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.The Lancet. Respiratory medicine · 2023Trial
- Long-term effectiveness and safety of cystic fibrosis transmembrane conductance regulator modulators and their impact on the lives of people with cystic fibrosis.American journal of respiratory and critical care medicine · 2026Article
- Proteomic Analysis of Three Independent Series of Sequential Cystic Fibrosis Strains in an International Pseudomonas aeruginosa Reference Panel Indicates Positive Selection in Late Infection Strains.MicrobiologyOpen · 2026Article
- Feasibility and Impact of a Coached Home-Based Exercise Program on Cardiorespiratory Fitness in Adults With Cystic Fibrosis on Highly Effective Modulator Therapy.CHEST pulmonary · 2026Article
- Elexacaftor-tezacaftor-ivacaftor for individuals with residual CFTR activity: an open-label, nonrandomized clinical trial.Annals of the American Thoracic Society · 2026Article
- Bridging the Gap in Eastern European Cystic Fibrosis Care: How Newborn Screening and Advanced CFTR Modulation Shape the Clinical Landscape in Western Romania.Children (Basel, Switzerland) · 2026Article
- Patient-Reported Health-Related Quality of Life in Romanian Patients with Cystic Fibrosis in the Era of Highly Effective CFTR Modulator Therapy: A National Cross-Sectional Mixed-Methods Survey.Journal of clinical medicine · 2026Article
- Effects of elexacaftor/tezacaftor/ivacaftor on the nasal microbial metagenome in cystic fibrosis.Microbiology spectrum · 2026Article
- Increased low-molecular-weight mucins in muco-obstructive airway disease limitInfection and immunity · 2026Article
- Meaningful Criteria to Persons Living With Cystic Fibrosis and Their Healthcare Providers in Helping Determine Adjustments to Routine Clinical Follow-Up.Pediatric pulmonology · 2026Article
- Investigating the Association Between Cystic Fibrosis and Colorectal Neoplasia: A Matched Case-Control Study.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Clinical Profile of Cystic Fibrosis in India: A Multi-Centric Prospective Study.Journal of paediatrics and child health · 2026Article
- Maternal, Infant, Reproductive and Child Health in Cystic Fibrosis (MATRIARCH_CF): a prospective, observational study to evaluate pregnancy and parenthood in females with cystic fibrosis and health of the offspring in the CFTR-modulator era.BMJ open respiratory research · 2026Observational
- Effectiveness of elexacaftor/tezacaftor/ivacaftor therapy in children and adolescents with cystic fibrosis and normal spirometry.Pediatric research · 2026Article
138 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on byReply to Martin2022
- Commented on by
Authors and funding
24 authors at 12 institutions in 2 countries.
David P NicholsDepartment of Pediatrics, and.ORCID 0000-0001-8611-7960
Alex C PaynterCystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, Washington.
Sonya L HeltsheDepartment of Pediatrics, and.
Scott H DonaldsonDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Carla A FrederickJacobs School of Medicine and Biomedical Sciences of the University of Buffalo, Buffalo, New York.
Steven D FreedmanBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Daniel GelfondWestern New York Pediatric Gastroenterology, Buffalo, New York.
Lucas R HoffmanDepartment of Pediatrics, and.
Andrea KellyDivision of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Michael R NarkewiczDigestive Health Institute, Children's Hospital Colorado, Aurora, Colorado.
Jessica E PittmanDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri.
Felix RatjenDivision of Respiratory Medicine, Department of Pediatrics, Translational Medicine, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Margaret RosenfeldDepartment of Pediatrics, and.
Scott D SagelDepartment of Pediatrics, Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0001-6172-4465
Sarah Jane SchwarzenbergDepartment of Pediatrics, Masonic Children's Hospital, University of Minnesota, Minneapolis, Minnesota.
Pradeep K SinghDepartment of Microbiology, School of Medicine, University of Washington, Seattle, Washington.
George M SolomonDepartment of Medicine.
Michael S StalveyThe Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, Alabama.
John P ClancyThe Cystic Fibrosis Foundation, Bethesda, Maryland.
Shannon KirbyCystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, Washington.
Jill M Van DalfsenCystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, Washington.
Margaret H KlosterCystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, Washington.
Steven M RoweDepartment of Medicine.ORCID 0000-0001-9045-0133
PROMISE Study group
Cystic Fibrosis Foundation · USUniversity of Alabama at Birmingham · USUniversity of Washington · USChildren's Hospital Colorado · USBeth Israel Deaconess Medical Center · USChildren's Hospital of Philadelphia · USHospital for Sick Children · CAJacobs Institute · USUniversity of Minnesota Children's Hospital · USUniversity of North Carolina at Chapel Hill · USVA Western New York Healthcare System · USWashington University in St. Louis · US
Funding
NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1MNational Dissemination of I-Corps@NCATS: Accelerating Translation through CommercializationUL1TR003096 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUTIERREZ, ORLANDO M, KIMBERLY, ROBERT P. · 2019 to 2023
$43.6MVector Core-Core 2P30DK054759 · NIDDK · UNIVERSITY OF IOWA · PI Alejandro Antonio Pezzulo · 1998 to 2026
$30.5MUAB CF Research and Translation Core CenterP30DK072482 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AMIT GAGGAR · 2007 to 2026
$23.0MTranslational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss, Lucas R Hoffman · 2010 to 2026
$21.4MTranslational Program in CFTR-Related Airway DiseasesR35HL135816 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROWE, STEVEN MARK · 2017 to 2022
$6.3MFunctional Categorization of Ciliary Motion in PCDK08HL138153 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SOLOMON, GEORGE MARTIN · 2019 to 2023
$799kNCATS NIH HHS UL1 TR002535NCATS NIH HHS UL1 TR003096NHLBI NIH HHS K08 HL138153NHLBI NIH HHS K24HL14166NHLBI NIH HHS R35 HL135816NIDDK NIH HHS P30 DK054759NIDDK NIH HHS P30 DK072482NIDDK NIH HHS P30 DK089507
Abstract
PubMed holds no abstract for this paper.
Indexed as
Cystic FibrosisAdultAminophenolsBenzodioxolesChildChloride Channel AgonistsChloridesCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsHumansIndolesMutationProspective StudiesPyrazolesPyridinesPyrrolidinesAminophenolsBenzodioxolesChloride Channel AgonistsChloridesCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationselexacaftorIndolesivacaftorPyrazolesPyridinesPyrrolidinesQuinolonestezacaftorclinical trialcystic fibrosiselexacaftor/tezacaftor/ivacaftormodulatorsPROMISE
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT06837181ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.